Zydus Therapeutics reports positive topline results from EPICS-III Phase 2(b)/3 Trial of… The trial met its primary composite endpoint, with a treatment difference in achieving a biochemical response of 48.5 per cent,…
3 Indian vaccines in phase-2 has created Apollo 11 moment for India: Dr V K Paul No pressure on regulators for approval of the vaccine, final call on allowing emergency use approval will be made on scientific…
